SINTX Technologies Partners with EVONIK for Innovative Implant Production
Milestone enables immediate production of SiN/PEEK custom devices
SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics and biomaterials company, has forged a groundbreaking supply agreement with EVONIK, a prestigious global leader in high-performance polymers. This collaboration focuses on the production of the innovative silicon nitride–PEEK compound (SiN/PEEK), which is specifically engineered for AI-assisted additive manufacturing of patient-specific implants. This production will take place at SINTX's U.S.-based facility, equipped for immediate manufacturing.
Through this partnership, EVONIK will leverage its extensive manufacturing capabilities to produce the SiN/PEEK compound to the exact specifications of SINTX. This allows SINTX to start the production of AI-designed, 3D-printed implants without delay. The demand for these custom devices is already apparent, with surgeons requesting humanitarian-use vertebral body replacement (VBR) implants for orthopedic and neurosurgical oncology patients.
Eric K. Olson, Chairman, President & CEO of SINTX, expressed his enthusiasm, stating, "This collaboration signifies a major advancement for SINTX and the realm of patient-specific implants. Combining EVONIK’s expertise in PEEK polymer manufacturing with our silicon nitride capabilities allows us to produce next-generation implants tailored to meet critical needs across various medical fields, including trauma, spine surgery, and oncology. The SiN/PEEK compound offers significant advantages over conventional PEEK, such as its antipathogenic properties, potential to support bone growth, and enhanced imaging capabilities, which are vital during complex procedures."
Benefits of SiN/PEEK for Patient-Specific Implants
The synergy between silicon nitride and PEEK is noteworthy in the medical field. SINTX’s research highlights the antipathogenic behaviors and osteogenic properties of silicon nitride, while PEEK is recognized for its radiolucency and mechanical adaptability. The combination of these materials aims to deliver:
Key Advantages
- Antipathogenic surfaces that decrease microbial adhesion on implants.
- Osteogenesis support that encourages bone growth and integration with the implant.
- Improved visualization during and after surgery compared to standard PEEK.
- Design flexibility through AI-assisted, additive manufacturing, enabling precise patient-specific geometries.
- Reliable filament technology for efficient, high-mix, and low-volume production tailored for customized needs.
With the supply agreement now active, both SINTX and EVONIK are eager to make the SiN/PEEK compound accessible to other qualified manufacturers. This broader availability aims to enhance clinical interventions where the specific attributes of silicon nitride can offer substantial clinical and economic benefits.
Immediate Focus on Humanitarian Applications
Currently, SINTX is prioritizing humanitarian efforts aimed at trauma and oncology cases, particularly post-tumor resections. Dr. Ryan Bock, SINTX's Chief Technology Officer, explains, "Our immediate projects in humanitarian use are responding directly to specific needs from surgeons in oncology. We believe that patient-specific designs can lead to better fitting and fixation, ultimately improving clinical outcomes. This focus allows us to refine our quality systems and regulatory pathways to expand into additional medical indications through established FDA procedures."
About EVONIK and SINTX Technologies
EVONIK, with its extensive network in the specialty chemicals sector, is committed to creating innovative solutions across more than 100 countries, employing about 5,000 staff members in North America alone. Their vision extends beyond mere chemistry; they aim to produce profitable, sustainable solutions that improve medical outcomes as exemplified by this collaboration with SINTX.
SINTX Technologies, headquartered in Salt Lake City, continues to lead in the advanced ceramics space, particularly in silicon nitride biomaterials. With a robust history of medical device implantation since 2008 and extensive research backing its products, SINTX is dedicated to enhancing clinical results and ensuring patient safety. The company remains focused on innovation and market diversification, including their recent FDA clearance for the SINAPTIC® Foot & Ankle Implant System.
Frequently Asked Questions
What is the SiN/PEEK compound?
The SiN/PEEK compound combines silicon nitride's unique properties with PEEK for enhanced performance in medical implants.
How will the agreement with EVONIK impact SINTX?
This partnership enables SINTX to leverage EVONIK's manufacturing expertise, accelerating the production of innovative patient-specific implants.
What are the key advantages of using SiN/PEEK in implants?
The compound offers antimicrobial characteristics, promotes bone integration, and provides better imaging capabilities than traditional materials.
What type of implants will be produced under this agreement?
The collaboration focuses on custom, patient-specific implants for applications in trauma and oncology.
Where can I learn more about SINTX Technologies?
For more information regarding SINTX's technologies and products, you can visit their official website.
